Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis

Clinical Nephrology

Volumn 73, Issue 2, 2010, Pages 131-138

  Kannampuzha, J ^a,d   Darling, P B ^a,d   Maguire, G F ^a   Donnelly, S ^a,b   McFarlane, P ^a,b   Chan, C T ^c   Connelly, P W ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Arylesterase activity; C reactive protein; Cardiovascular disease; Home nocturnal hemodialysis; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; C REACTIVE PROTEIN; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRY WEIGHT; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HIGH RISK PATIENT; HOME DIALYSIS; HUMAN; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS;

EID: 76649139460     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 1993; 211: 871-879.
2. Canales A, Sanchez-Muniz FJ. Paraoxanase, something more than an enzyme? Med Clin (Barc). 2003; 121: 537-548.
3. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-1247.
4. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med. 1981; 305: 1176-1181.
5. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005; 44: 6371-6382.
6. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993; 3: 73-76.
7. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol. 1998; 31: 329-336.
8. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008; 299: 1265-1276.
9. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ. Combined serum paraoxonase kockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000; 275: 17527-17535.
10. Paragh G, Seres I, Balogh Z, Varga Z, Karpati I, Matyus J et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron. 1998; 80: 166-170.
11. Clermont G, Lecour S, Lahet J, Siohan P, Vergely C, Chevet D, RifleG, Luc R. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res. 2000; 47: 618-623.
12. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int. 2001; 59: 407-414.
13. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Focà A, Paroni R, Malatino LS. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens. 2000; 18: 1207-1213.
14. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35: 469-476.
15. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658.
16. Ikeda Y, Suehiro T, Itahara T, Inui Y, Chikazawa H, Inoue M, Arii K, Hashimoto K. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol. 2007; 67: 358-365.
17. Dirican M, Akça R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol. 2004; 17: 813-818.
18. Juretic D, Tadijanovic M, Rekic B, Simeon-Rudolf V, Reiner E, Baricic M. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J. 2001; 42: 146-150.
19. Schiavon R, Defanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta. 1996; 247: 71-80.
20. Itahara T, Suehiro T, Ikeda Y, Inoue M, Nakamura T, Kumon Y, Kawada M, Hashimoto K. Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb. 2000; 7: 152-158.
21. Mackness B, Hine D, McElduff P, Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis. 2006; 186: 396-401.
22. Pierratos A. Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant. 1999, 14: 2835-2840.
23. Kannampuzha J, Donnelly S, McFarlane P, Chan C, House JD, Pencharz PB, Darling PB. Glutathione and riboflavin status in supplemented patients undergoing home nocturnal hemodialysis versus standard hemodialysis. J Ren Nutr. In press. doi: 10.1053/j.jrn.2009.09.002.
24. Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res. 2008; 49:245-250.
25. Filler G, Bokenkamp A, Hofmann W, Le BT, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem. 2005; 38: 1-8.
26. 2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem. 1982; 28: 1379-1388.
27. Bugeja AL, Chan CT. Improvement in lipid profile by nocturnal hemodialysis in patients with end-stage renal disease. ASAIO J. 2004; 50: 328-331.
28. Gugliucci A, Lunceford N, Kinugasa E, Ogata H, Schulze J, Kimura S. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta. 2007; 384: 105-112.
29. Horoz M, Aslan M, Selek S, Koylu AO, Bolukbas C, Bolukbas FF, Celik H, Erel O. PON1 status in haemodialysis patients and the impact of hepatitis C infection. Clin Biochem. 2007; 40: 609-614.
30. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 1998; 139: 307-315.
31. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM. Oxidized phospholipids induce changes in hepatic paraoxonase and apo A-I but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem. 2001; 276: 1923-1929.
32. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W. European UremicToxinWork Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63: 1934-1943.
33. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347: 2010-2019.
34. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006; 17: 546-555.